ECO 2026: targeting organs, not just weight, defines next wave of obesity therapy

Industry symposia echoed this year’s ECO focus on shifting the obesity management framework towards organ-level intervention. Two companies, Madrigal and Novo Nordisk, drew physicians’ attention to the risk of patients with obesity developing MASH. Madrigal’s decision to sponsor a symposium at ECO reflects a deliberate effort to engage prescribers beyond the hepatology community. Credit: Piotr Swat / Shutterstock.com. The European Congress on Obesity (ECO) 2026 has historically focused primarily on weight reduction. However, this year, a shift in tone was evident with obesity increasingly being framed not as a condition defined by body mass index (BMI), but as a systemic…

Source: Clinical Trials Arena